Imunon (IMNN) to Announce Quarterly Earnings on Tuesday

Imunon (NASDAQ:IMNN) is anticipated to release its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of ($0.8675) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 11:00 AM ET.

Imunon (NASDAQ:IMNN) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.38. On average, analysts expect Imunon to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Imunon Price Performance

Shares of IMNN stock opened at $1.59 on Monday. The company’s fifty day moving average price is $1.90 and its two-hundred day moving average price is $2.65. The firm has a market capitalization of $6.68 million, a P/E ratio of -0.31 and a beta of 1.97. Imunon has a 12 month low of $1.47 and a 12 month high of $8.19.

Analysts Set New Price Targets

IMNN has been the topic of several recent analyst reports. Maxim Group set a $10.00 price target on Imunon and gave the stock a “buy” rating in a research note on Friday, April 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Investors Weigh In On Imunon

An institutional investor recently bought a new stake in Imunon stock. Armistice Capital LLC purchased a new position in shares of Imunon, Inc. (NASDAQ:IMNN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned about 8.69% of Imunon as of its most recent filing with the Securities and Exchange Commission (SEC). 4.47% of the stock is currently owned by institutional investors.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.